Title (en)

ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF

Title (de)

VERBESSERTER CHIMÄRER ANTIGENREZEPTOR FÜR DIE IMMUNEFFEKTORZELLZÜCHTUNG UND SEINE VERWENDUNG

Title (fr)

RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE AMÉLIORÉ POUR L'INGÉNIERIE DE CELLULES EFFECTRICES IMMUNITAIRES ET SON UTILISATION

Publication

EP 4045539 A4 20240313 (EN)

Application

EP 20877752 A 20201019

Priority

- US 201962916468 P 20191017
- US 2020054601 W 20201007
- US 2020056387 W 20201019

Abstract (en)

[origin: WO2021077117A1] Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

IPC 8 full level

C07K 14/705 (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01); **C12N 5/0783** (2010.01)

CPC (source: EP US)

A61K 39/3955 (2013.01 - US); **A61K 39/4611** (2023.05 - EP US); **A61K 39/4613** (2023.05 - EP US); **A61K 39/4631** (2023.05 - EP US); **A61K 39/464401** (2023.05 - EP US); **A61K 39/464411** (2023.05 - EP US); **A61K 39/464429** (2023.05 - EP US); **A61K 2239/57** (2023.05 - US); **A61P 35/00** (2018.01 - EP US); **C07K 14/70503** (2013.01 - EP US); **C07K 14/70507** (2013.01 - US); **C07K 14/7051** (2013.01 - EP US); **C07K 14/70517** (2013.01 - US); **C07K 14/70521** (2013.01 - US); **C07K 14/70535** (2013.01 - US); **C07K 14/70578** (2013.01 - US); **C07K 14/7155** (2013.01 - US); **C07K 16/22** (2013.01 - US); **C07K 16/28** (2013.01 - EP); **C07K 16/2803** (2013.01 - US); **C07K 16/2827** (2013.01 - US); **C07K 16/2833** (2013.01 - US); **C07K 16/2863** (2013.01 - US); **C07K 16/2866** (2013.01 - US); **C07K 16/2878** (2013.01 - US); **C07K 16/2887** (2013.01 - US); **C07K 16/2893** (2013.01 - US); **C07K 16/2896** (2013.01 - US); **C07K 16/3069** (2013.01 - US); **C07K 16/3084** (2013.01 - US); **C07K 16/32** (2013.01 - US); **C12N 5/0636** (2013.01 - US); **C12N 5/0646** (2013.01 - EP US); A61K 48/005 (2013.01 - EP); A61K 2239/22 (2023.05 - EP); A61K 2239/57 (2023.05 - EP); C07K 2317/622 (2013.01 - EP); C07K 2319/02 (2013.01 - US); C07K 2319/03 (2013.01 - EP US); C12N 2506/45 (2013.01 - EP US); C12N 2510/00 (2013.01 - EP US)

Citation (search report)

- [E] WO 2021194495 A1 20210930 - US HEALTH [US]
- [A] YE LI ET AL: "Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity", CELL STEM CELL, vol. 23, no. 2, 28 June 2018 (2018-06-28), AMSTERDAM, NL, pages 181 - 192, XP055700643, ISSN: 1934-5909, DOI: 10.1016/j.stem.2018.06.002
- [XPI] ZHUANG XIAOXUAN ET AL: "Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. TRENDS JOURNALS, GB, vol. 40, no. 12, 12 November 2019 (2019-11-12), pages 1078 - 1081, XP085925690, ISSN: 1471-4906, [retrieved on 20191112], DOI: 10.1016/J.IT.2019.10.004
- See also references of WO 2021077117A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2021077117 A1 20210422; CN 114901693 A 20220812; EP 4045539 A1 20220824; EP 4045539 A4 20240313; JP 2022552314 A 20221215; US 2024131156 A1 20240425; US 2024226293 A9 20240711

DOCDB simple family (application)

US 2020056387 W 20201019; CN 202080090875 A 20201019; EP 20877752 A 20201019; JP 2022521958 A 20201019; US 202017769651 A 20201019